Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5-aminolaevulinic acid: Implications for photodynamic treatment

British Journal of Dermatology

Volumn 137, Issue 5, 1997, Pages 736-742

  Ross, E V ^a,c   Romero, R ^a   Kollias, N ^a   Crum, C ^b   Rox Anderson, R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; PROTOPORPHYRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG PENETRATION; DRUG SELECTIVITY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; SKIN DEFECT; SKIN INFLAMMATION; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION; WART VIRUS;

EID: 0030662303     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb01110.x     Document Type: Article

References (31)

1. Fergin P. Photodynamic therapy for psoriasis? [Review] Austral J Dermatol 1996; 37: 87-8.
2. Lui H. Photodynamic therapy in dermatology with porfimer sodium and benzoporphyrin derivative: an update. [Review] Semin Oncol 1994; 21: 11-14.
3. Boehncke WH, Konig K, Kaufmann R et al. Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo. Arch Dermatol Res 1994; 286: 300-3.
4. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX. a clinically useful photosensitizer for photodynamic therapy. [Review] J Photochem Photobiol 1992; 14B: 275-92.
5. Ferenczy A. Epidemiology and clinical pathophysiology of condyloma acuminata. Am J Obstetr Gynecol 1995; 172: 1333-8.
6. Greenberg M, Rutledge L. Understanding human papillomaviral infections in women. Semin Dermatol 1992; 11: 241-6.
7. Rosenberg S. Sexually transmittted papillomaviral infection in men. Dermatol Clinics 1991; 9: 317-31.
8. Frank RG. Photodynamic therapy for condylomata acuminata with local application of 5-aminolevulinic acid. Genitourinary Med 1996; 72: 70-1.
9. Lungu O, Wright T, Silverstein S. Typing of human papillomavirus by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. Mol Cell Probes 1992; 6: 145-52.
10. Genest D, Stein L, Cibas E et al. A binary (Bethesda) system for cervical precursor classification: reproducibility and viral correlates. Hum Pathol 1993; 24: 730-6.
11. Ferenczy A, Mitao M, Nagai N et al. Latent papillomavirus and recurring genital warts. N Engl J Med 1985; 313: 784-8.
12. Krogh GV. Clinical relevance and evaluation of genitoanal papilloma virus infection in the male. Semin Dermatol 1992; 11: 229-40.
13. Ferenczy A. Laser treatment of genital papillomavirus infections in the male patient. Obstet Gynecol Clin North Am 1991; 18: 525-35.
14. Garden J, O'Banion M, Shelnitz L et al. Papilloma virus in the vapor of carbon dioxide laser-treated verrucae. JAMA 1988; 259: 1199-202.
15. Svaasand LO. Dosimetry model for photodynamic therapy with topically administered photosensitizers. Lasers Surg Med 1996; 18: 139-49.
16. Schultz RE. Clinical and molecular evaluation of acetowhite genital lesions in men. J Urol 1990; 143: 920-3.
17. Barry B. Properties that influence percutaneous absorption. In: Dermatological Formulations: Percutaneous Absorption (Barry B, ed.). New York: Marcel Dekker, 1983: 145-6.
18. Stringer MR, Collins P, Robinson D et al. The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential fur superficial photodynamic therapy. J Invest Dermatol 1996; 107: 76-81.
19. Svanberg K, Andersson T, Killander D et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 1994; 130: 743-51.
20. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol 1995; 29B: 53-7.
21. Bernstein E, Thomas G, Smith P et al. Reponse of black and white guinea pig skin to photodynamic treatment using 514 nm light and dihematoporphyrin ether. Arch Dermatol 1990; 126: 1303-7.
22. Berardesca E. Racial differences in skin pathology. J Am Acad Dermatol 1996; 34: 667-72.
23. Konig K, Schneckenburger H, Ruck A, Steiner R. In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins. J Photochem Photobiol 1993; 18B: 287-90.
24. Charlesworth P, Truscott TG. The use of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT). J Photochem Photobiol 1993; 18B: 99-100.
25. Iunuma S, Farshi S, Ortel B, Hasan T, A mechanistic study of cellular photodestruction with 5-aminolevulinic acid-induced porphyrin. Br J Cancer 1994; 70: 21-8.
26. Steinbach P. Cellular fluorescence of the endogenous photosensitzer protoporphyrin IX following exposure to 5-aminolevulinic acid. Photochem Photobiol 1995; 62: 887-95.
27. Szeimies RM, Abels C, Fritsch C et al. Wavelength dependency of photodynamic effects after sensitization with 5-aminolevulinic acid in vitro and in vivo. J Invest Dermatol 1995; 105: 672-7.
28. Henderson BW, Vaughan L, Bellnier DA et al. Photosensitization of murine tumor, vasculature and skin by 5-aminolevulinic acid-induced porphyrin. Photochem Photobiol 1995; 62: 780-9.
29. North J, Neyndorff H, King D, Levy JG. Viral inactivation in blood and red cell concentrates with benzoporphyrin derivative. Blood Cells 1992; 18: 129-40.
30. Lofgren LA, Ronn AM, Nouri M et al. Efficacy of intravenous delta-aminolaevulinic acid photodynamic therapy on rabbit papillomas. Br J Cancer 1995; 72: 857-64.
31. Gaspard S, Tempete C, Werner G. Studies on photoinactivation by various phthalocyanines of a free or replicating enveloped virus. J Photochem Photobiol 1995; 31B: 159-62.